CAR-T Meeting 2024 | First-in-human tandem expanded-NK and BCMA-CAR-NK cell infusion
Antonio Carrasco-Yalán, MD, British American Clinic, San Isidro, Peru, discusses a new natural killer (NK)-cell product engineered from NK-cells and a second generation CAR using a lipid nanoparticle (LNP) technology platform that allows for efficient delivery of anti-BCMA mRNA into the expanded-NK cells. Dr Carrasco-Yalán comments on the curative potential of this first-in-human tandem expanded-NK and BCMA-CAR-NK cell infusion, highlighting the benefits of this approach in patients who are not eligible for or do not have access to CAR-T. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Investigator: MSD; Speaker: MSN, varifarma; Advisor: Immunovacell.
